Table 3. Clinical Outcomes for Cohorts, Family History, and HR-DDR Status.
58 patients total were evaluable for response. Of those 58 patients, several subgroups, as detailed, were compared for the objective response rate (ORR), disease control rate (DCR, defined as partial response or complete response at any time, or stable disease at 2 months), median progression-free survival (PFS), and median overall survival (OS).
| Subgroup (n) | ORR (%) | DCR (%) | PFS (mos) | OS (mos) |
|---|---|---|---|---|
| All Response Evaluable Patients (58) | 26 | 52 | 4.4 | 7.8 |
| Phase I Patients (25) | 20 | 48 | 4.0 | 6.5 |
| Phase II Untreated (15) | 40 | 87 | 6.5 | 15.0 |
| Phase II Previously Treated (18) | 22 | 28 | 1.8 | 4.6 |
| Prior Platinums | ||||
| Exposure to Prior Platinum (14) | 7 | 14 | 2.1 | 5.3 |
| Non-Progression on Prior Platinum (4) | 25 | 50 | 5.5 | 6.7 |
| Progression on Prior Platinum (10) | 0 | 0 | 1.5 | 4.0 |
| No Prior Platinum (44) | 32 | 64 | 5.5 | 8.8 |
| Family History (FH) | ||||
| (+) FH (43) | 30 | 53 | 5.4 | 9.5 |
| No FH (15) | 13 | 47 | 3.8 | 5.5 |
| HR-DDR Mutations | ||||
| HR-DDR mutated (18) | 44 | 61 | 6.0 | 10.4 |
| Non-Mutated/Unknown (40) | 18 | 48 | 3.6 | 6.9 |
| HR-DDR Mutated, No progression on prior platinum (14) | 57 | 79 | 8.4 | 11.2 |